PPARA and metabolic dysfunction-associated steatohepatitis: While previous studies have compared GLP-1R/GCGR and GLP-1R agonists, the current study appears to be the first to directly compare a GLP-1R/GCGR and a PPAR-α/δ agonist, demonstrating statistically improved activity of ALT-801 over elafibranor in most NASH measures.